Loading...

Illumina

Nasdaq:ILMN
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ILMN
Nasdaq
$44B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The last earnings update was 87 days ago. More info.


Add to Portfolio Compare Print
  • Illumina has significant price volatility in the past 3 months.
ILMN Share Price and Events
7 Day Returns
-1.3%
NasdaqGS:ILMN
-0.7%
US Life Sciences
-1.2%
US Market
1 Year Returns
-4.1%
NasdaqGS:ILMN
19.1%
US Life Sciences
3.3%
US Market
ILMN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Illumina (ILMN) -1.3% -17.5% -7.4% -4.1% 98% 79.6%
US Life Sciences -0.7% -4.2% 5% 19.1% 80.6% 108.7%
US Market -1.2% 0.8% 0.9% 3.3% 35.9% 41.7%
1 Year Return vs Industry and Market
  • ILMN underperformed the Life Sciences industry which returned 19.1% over the past year.
  • ILMN underperformed the Market in United States of America which returned 3.3% over the past year.
Price Volatility
ILMN
Industry
5yr Volatility vs Market

ILMN Value

 Is Illumina undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Illumina to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Illumina.

NasdaqGS:ILMN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 15 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:ILMN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.02 (1 + (1- 21%) (5.73%))
1.045
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.045 * 5.96%)
8.96%

Discounted Cash Flow Calculation for NasdaqGS:ILMN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Illumina is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:ILMN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.96%)
2020 1,063.82 Analyst x5 976.37
2021 1,356.63 Analyst x5 1,142.77
2022 1,624.10 Analyst x1 1,255.62
2023 1,841.57 Est @ 13.39% 1,306.71
2024 2,029.26 Est @ 10.19% 1,321.53
2025 2,190.65 Est @ 7.95% 1,309.37
2026 2,330.56 Est @ 6.39% 1,278.48
2027 2,453.83 Est @ 5.29% 1,235.46
2028 2,564.78 Est @ 4.52% 1,185.17
2029 2,666.97 Est @ 3.98% 1,131.09
Present value of next 10 years cash flows $12,142.56
NasdaqGS:ILMN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $2,666.97 × (1 + 2.73%) ÷ (8.96% – 2.73%)
$44,003.74
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $44,003.74 ÷ (1 + 8.96%)10
$18,662.46
NasdaqGS:ILMN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $12,142.56 + $18,662.46
$30,805.02
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $30,805.02 / 147.00
$209.56
NasdaqGS:ILMN Discount to Share Price
Calculation Result
Value per share (USD) From above. $209.56
Current discount Discount to share price of $298.28
= -1 x ($298.28 - $209.56) / $209.56
-42.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Illumina is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Illumina's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Illumina's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ILMN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $5.79
NasdaqGS:ILMN Share Price ** NasdaqGS (2019-07-22) in USD $298.28
United States of America Life Sciences Industry PE Ratio Median Figure of 22 Publicly-Listed Life Sciences Companies 39.39x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Illumina.

NasdaqGS:ILMN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ILMN Share Price ÷ EPS (both in USD)

= 298.28 ÷ 5.79

51.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Illumina is overvalued based on earnings compared to the US Life Sciences industry average.
  • Illumina is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Illumina's expected growth come at a high price?
Raw Data
NasdaqGS:ILMN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 51.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts
18.6%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 20 Publicly-Listed Life Sciences Companies 2.7x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

NasdaqGS:ILMN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 51.52x ÷ 18.6%

2.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Illumina is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Illumina's assets?
Raw Data
NasdaqGS:ILMN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $27.11
NasdaqGS:ILMN Share Price * NasdaqGS (2019-07-22) in USD $298.28
United States of America Life Sciences Industry PB Ratio Median Figure of 38 Publicly-Listed Life Sciences Companies 4.69x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.79x
NasdaqGS:ILMN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ILMN Share Price ÷ Book Value per Share (both in USD)

= 298.28 ÷ 27.11

11x

* Primary Listing of Illumina.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Illumina is overvalued based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess Illumina's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Illumina has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ILMN Future Performance

 How is Illumina expected to perform in the next 1 to 3 years based on estimates from 15 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Illumina expected to grow at an attractive rate?
  • Illumina's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Illumina's earnings growth is expected to exceed the United States of America market average.
  • Illumina's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ILMN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ILMN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts 18.6%
NasdaqGS:ILMN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts 11.9%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 16.2%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ILMN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ILMN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 5,664 1
2022-12-31 5,398 1,998 1,556 2
2021-12-31 4,675 1,699 1,399 9
2020-12-31 4,128 1,373 1,075 15
2019-12-31 3,622 1,132 923 15
NasdaqGS:ILMN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 3,397 1,085 851
2018-12-30 3,333 1,142 826
2018-09-30 3,243 1,136 684
2018-07-01 3,103 1,079 648
2018-04-01 2,936 962 567
2017-12-31 2,752 875 725
2017-10-01 2,594 843 775
2017-07-02 2,487 784 741
2017-04-02 2,424 848 730
2017-01-01 2,398 779 454
2016-10-02 2,371 757 440
2016-07-03 2,314 762 430
2016-04-03 2,253 692 415

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Illumina's earnings are expected to grow by 18.6% yearly, however this is not considered high growth (20% yearly).
  • Illumina's revenue is expected to grow by 11.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ILMN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below

All data from Illumina Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ILMN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 10.92 10.92 10.92 1.00
2021-12-31 9.36 12.92 8.15 5.00
2020-12-31 7.15 7.79 6.84 8.00
2019-12-31 6.18 6.69 5.85 8.00
NasdaqGS:ILMN Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 5.79
2018-12-30 5.62
2018-09-30 4.66
2018-07-01 4.42
2018-04-01 3.88
2017-12-31 4.97
2017-10-01 5.30
2017-07-02 5.06
2017-04-02 4.97
2017-01-01 3.09
2016-10-02 3.00
2016-07-03 2.94
2016-04-03 2.85

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Illumina is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Illumina's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Illumina has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ILMN Past Performance

  How has Illumina performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Illumina's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Illumina has delivered over 20% year on year earnings growth in the past 5 years.
  • Illumina's 1-year earnings growth exceeds its 5-year average (49.6% vs 21.1%)
  • Illumina's earnings growth has exceeded the US Life Sciences industry average in the past year (49.6% vs 45.3%).
Earnings and Revenue History
Illumina's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Illumina Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ILMN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 3,397.00 851.00 877.00 600.00
2018-12-30 3,333.00 826.00 849.00 568.00
2018-09-30 3,243.00 684.00 799.00 538.00
2018-07-01 3,103.00 648.00 769.00 513.00
2018-04-01 2,936.00 567.00 732.00 492.00
2017-12-31 2,752.00 725.00 720.00 495.00
2017-10-01 2,594.00 775.00 692.00 488.00
2017-07-02 2,487.00 741.00 664.00 480.00
2017-04-02 2,424.00 730.00 652.00 474.00
2017-01-01 2,398.00 454.00 630.00 458.00
2016-10-02 2,370.55 440.49 623.75 449.85
2016-07-03 2,313.82 429.62 621.40 423.07
2016-04-03 2,253.20 414.87 596.84 395.26
2016-01-03 2,220.00 462.00 561.00 362.00
2015-09-27 2,140.59 510.31 532.78 348.13
2015-06-28 2,070.95 485.67 516.02 333.98
2015-03-29 1,979.14 430.03 506.23 320.79
2014-12-28 1,861.36 353.35 499.48 306.06
2014-09-28 1,736.31 280.73 478.49 293.62
2014-06-29 1,612.48 218.60 453.20 279.39
2014-03-30 1,511.00 207.87 429.64 264.18
2013-12-29 1,421.18 125.31 422.76 248.64
2013-09-29 1,343.12 116.55 377.68 212.45
2013-06-30 1,272.19 114.94 356.08 194.90
2013-03-31 1,206.70 102.47 340.72 197.62
2012-12-30 1,148.52 151.25 324.80 184.77
2012-09-30 1,089.32 91.07 285.65 216.68

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Illumina has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Illumina used its assets more efficiently than the US Life Sciences industry average last year based on Return on Assets.
  • Illumina's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Illumina's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Illumina has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ILMN Health

 How is Illumina's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Illumina's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Illumina is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Illumina's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Illumina's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Illumina Company Filings, last reported 3 months ago.

NasdaqGS:ILMN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 4,107.00 1,743.00 3,615.00
2018-12-30 3,906.00 1,728.00 3,512.00
2018-09-30 3,812.00 1,967.00 3,389.00
2018-07-01 3,568.00 1,348.00 2,512.00
2018-04-01 3,288.00 1,330.00 2,373.00
2017-12-31 2,969.00 1,079.00 2,145.00
2017-10-01 2,979.00 1,182.00 2,041.00
2017-07-02 2,795.00 1,174.00 1,893.00
2017-04-02 2,610.00 1,056.00 1,778.00
2017-01-01 2,314.00 1,058.00 1,559.00
2016-10-02 2,353.93 1,042.02 1,536.27
2016-07-03 2,173.65 1,031.88 1,425.26
2016-04-03 2,104.31 1,022.65 1,343.09
2016-01-03 1,881.10 1,090.58 1,386.22
2015-09-27 1,968.70 1,110.10 1,439.41
2015-06-28 1,793.91 1,303.28 1,510.38
2015-03-29 1,623.33 1,301.20 1,366.49
2014-12-28 1,462.80 1,291.04 1,338.37
2014-09-28 1,274.31 1,280.96 1,271.43
2014-06-29 1,080.44 1,270.96 1,103.06
2014-03-30 1,573.61 848.02 1,091.80
2013-12-29 1,533.20 868.59 1,165.60
2013-09-29 1,374.46 859.50 1,027.99
2013-06-30 1,388.59 851.90 1,129.46
2013-03-31 1,311.83 851.38 1,067.47
2012-12-30 1,318.58 842.37 1,350.20
2012-09-30 1,222.21 833.47 1,233.07
  • Illumina's level of debt (42.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (54.9% vs 42.4% today).
  • Debt is well covered by operating cash flow (62.2%, greater than 20% of total debt).
  • Illumina earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Illumina's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Illumina has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ILMN Dividends

 What is Illumina's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Illumina dividends. Estimated to be 0% next year.
If you bought $2,000 of Illumina shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Illumina's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Illumina's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ILMN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ILMN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Illumina has not reported any payouts.
  • Unable to verify if Illumina's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Illumina's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Illumina has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Illumina's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Illumina's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Illumina afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Illumina has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ILMN Management

 What is the CEO of Illumina's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Francis deSouza
COMPENSATION $11,067,566
AGE 48
TENURE AS CEO 3 years
CEO Bio

Mr. Francis A. deSouza has been the Chief Executive Officer of Illumina Inc. since July 5, 2016 and as its President since December, 2013. Mr. deSouza served as President of Products & Services at Symantec Corporation until December 1, 2013. He served as Group President of Enterprise Products & Services of Symantec Corporation since May 2011. He began his career at IBM. He served as Senior Vice President of Enterprise Security Group of Symantec Corporation from January 2009 to May 2011 and also served as Senior Vice President of Information Risk Management. Mr. deSouza served as the Chief Executive Officer at IMlogic Inc. Mr. deSouza served as Senior Vice President Information Foundation Compliance & Security Management Group at Symantec Corporation. He leads engineering, product management, field enablement, business development and operations for Symantec's compliance and security management, messaging security and archiving businesses. He co-founded IMlogic,Inc. in 2001. He joined Symantec through the acquisition of IMlogic in February 2006. He served as Product Unit Manager at Microsoft, directing a team in the development of the enterprise real-time communications platform, including instant messaging, chat, Voice over IP and NetMeeting. He serves as a Member of Advisory Board of Kodiak Venture Partners. He founded Flash Communications, which quickly emerged as a leader in the corporate instant messaging space and was acquired by Microsoft in 1998. He has been a Director of Illumina Inc. since January 2014. He serves as a Director of OptiMEMS, Inc. He served as a Director of Citrix Systems, Inc. since December 2014 until June 23, 2016. He served as a Director of VeriSign Japan k.k. since March 2011. He served as a Director of Symantec Website Security G.K. since March 2011. He was employee at Terion, Inc. He served as a Director at IMlogic Inc. Mr. deSouza graduated from the Massachusetts Institute of Technology (MIT) with BS and MS degrees in Electrical Engineering and Computer Science.

CEO Compensation
  • Francis's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Francis's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Illumina management team in years:

1.7
Average Tenure
50
Average Age
  • The average tenure for the Illumina management team is less than 2 years, this suggests a new team.
Management Team

Jay Flatley

TITLE
Executive Chairman
COMPENSATION
$3M
AGE
66

Francis deSouza

TITLE
CEO, President & Director
COMPENSATION
$11M
AGE
48
TENURE
3 yrs

Sam Samad

TITLE
CFO & Senior VP
COMPENSATION
$3M
AGE
49
TENURE
2.5 yrs

Omead Ostadan

TITLE
Senior Vice President of Products
COMPENSATION
$5M
AGE
47
TENURE
0.5 yrs

Aimee Hoyt

TITLE
Chief People Officer & Senior VP
COMPENSATION
$4M
AGE
48
TENURE
1.5 yrs

Garret Hampton

TITLE
Senior Vice President of Clinical Genomics
COMPENSATION
$4M
AGE
53
TENURE
2.5 yrs

Bob Ragusa

TITLE
Senior Vice President of Global Quality and Operations
AGE
59
TENURE
0.5 yrs

Paula Dowdy

TITLE
Senior VP & GM of Commercial Operations-Europe
TENURE
0.5 yrs

Karen McGinnis

TITLE
VP & Chief Accounting Officer
AGE
52
TENURE
1.7 yrs

Mostafa Ronaghi

TITLE
CTO & Senior VP
COMPENSATION
$3M
AGE
50
TENURE
11.5 yrs
Board of Directors Tenure

Average tenure and age of the Illumina board of directors in years:

3
Average Tenure
60
Average Age
  • The tenure for the Illumina board of directors is about average.
Board of Directors

Jay Flatley

TITLE
Executive Chairman
COMPENSATION
$3M
AGE
66
TENURE
3 yrs

Francis deSouza

TITLE
CEO, President & Director
COMPENSATION
$11M
AGE
48
TENURE
5.5 yrs

Rob Epstein

TITLE
Independent Director
COMPENSATION
$489K
AGE
64
TENURE
6.7 yrs

Frances Arnold

TITLE
Independent Director
COMPENSATION
$472K
AGE
62
TENURE
3.5 yrs

Caroline Dorsa

TITLE
Independent Director
COMPENSATION
$476K
AGE
60
TENURE
2.5 yrs

Gary Guthart

TITLE
Director
COMPENSATION
$468K
AGE
53
TENURE
1.6 yrs

John Thompson

TITLE
Lead Independent Director
COMPENSATION
$487K
AGE
70
TENURE
1.2 yrs

Phil Schiller

TITLE
Independent Director
COMPENSATION
$467K
AGE
59
TENURE
3 yrs

Sue Siegel

TITLE
Director
AGE
58
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Illumina's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Illumina has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ILMN News

Simply Wall St News

How Does Illumina, Inc.'s (NASDAQ:ILMN) Earnings Growth Stack Up Against Industry Performance?

Today I will assess ILMN's latest performance announced on 31 March 2019 and compare these figures to its longer term trend and industry movements. … View our latest analysis for Illumina How ILMN fared against its long-term earnings performance and its industry ILMN's trailing twelve-month earnings (from 31 March 2019) of US$851m has jumped 50% compared to the previous year. … I recommend you continue to research Illumina to get a more holistic view of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for ILMN’s future growth?

Simply Wall St -

Illumina (NASDAQ:ILMN) Shareholders Have Enjoyed An Impressive 153% Share Price Gain

(NASDAQ:ILMN) share price is 153% higher than it was three years ago. … By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … During three years of share price growth, Illumina achieved compound earnings per share growth of 27% per year.

Simply Wall St -

Here's What Illumina, Inc.'s (NASDAQ:ILMN) P/E Is Telling Us

View our latest analysis for Illumina How Do I Calculate Illumina's Price To Earnings Ratio? … The formula for price to earnings is: Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS) Or for Illumina: P/E of 63.59 = $368.15 ÷ $5.79 (Based on the trailing twelve months to March 2019.) Is A High Price-to-Earnings Ratio Good? … All else being equal, it's better to pay a low price -- but as Warren Buffett said, 'It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price.' How Growth Rates Impact P/E Ratios P/E ratios primarily reflect market expectations around earnings growth rates.

Simply Wall St -

Is It Too Late To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

NasdaqGS:ILMN Past and Future Earnings, June 21st 2019 Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. … Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. … If you believe ILMN should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable.

Simply Wall St -

What Should We Expect From Illumina, Inc.'s (NASDAQ:ILMN) Earnings In The Year Ahead?

Generally, the consensus outlook from analysts appear somewhat bearish, with earnings expected to grow by 16% in the upcoming year compared with the higher past 5-year average growth rate of 21%. … To reduce the year-on-year volatility of analyst earnings forecast, I've inserted a line of best fit through the expected earnings figures to determine the annual growth rate from the slope of the line. … NasdaqGS:ILMN Past and Future Earnings, June 11th 2019 This results in an annual growth rate of 18% based on the most recent earnings level of US$826m to the final forecast of US$1.4b by 2022.

Simply Wall St -

Do Illumina's (NASDAQ:ILMN) Earnings Warrant Your Attention?

See our latest analysis for Illumina How Fast Is Illumina Growing? … Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. … Further, the high level of insider buying impresses me, and suggests that I'm not the only one who appreciates the EPS growth.

Simply Wall St -

Is Illumina, Inc. (NASDAQ:ILMN) Undervalued After Accounting For Its Future Growth?

As Warren Buffett’s right-hand man Charlie Munger said, “No matter how wonderful a business is, it’s not worth an infinite price.” Illumina is available at price-to-earnings ratio of 52.94x, showing us it is overvalued compared to the US market average ratio of 17.74x , and overvalued based on current earnings compared to the Life Sciences industry average of 34.28x. … NasdaqGS:ILMN Price Estimation Relative to Market, May 22nd 2019 After looking at ILMN's value based on current earnings, we can see it seems overvalued relative to other companies in the industry. … So, when we include the growth factor in our analysis, Illumina appears overvalued , based on the fundamentals.

Simply Wall St -

Is Illumina, Inc. (NASDAQ:ILMN) Overpaying Its CEO?

Francis deSouza has been the CEO of Illumina, Inc. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other big companies. … How Does Francis deSouza's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Does Illumina, Inc.'s (NASDAQ:ILMN) Recent Track Record Look Strong?

After reading Illumina, Inc.'s (NASDAQ:ILMN) most recent earnings announcement (30 December 2018), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … Did ILMN's recent earnings growth beat the long-term trend and the industry. … However, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 23%, indicating the rate at which ILMN is growing has slowed down

Simply Wall St -

Should You Be Excited About Illumina, Inc.'s (NASDAQ:ILMN) 20% Return On Equity?

This article is for those who would like to learn about Return On Equity (ROE). … That means that for every $1 worth of shareholders' equity, it generated $0.20 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

ILMN Company Info

Description

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Details
Name: Illumina, Inc.
ILMN
Exchange: NasdaqGS
Founded: 1998
$43,847,160,000
147,000,000
Website: http://www.illumina.com
Address: Illumina, Inc.
5200 Illumina Way,
San Diego,
California, 92122,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ILMN Common Stock Nasdaq Global Select US USD 28. Jul 2000
DB ILU Common Stock Deutsche Boerse AG DE EUR 28. Jul 2000
LSE 0J8Z Common Stock London Stock Exchange GB USD 28. Jul 2000
WBAG ILMN Common Stock Wiener Boerse AG AT EUR 28. Jul 2000
BMV ILMN * Common Stock Bolsa Mexicana de Valores MX MXN 28. Jul 2000
Number of employees
Current staff
Staff numbers
7,300
Illumina employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 23:41
End of day share price update: 2019/07/22 00:00
Last estimates confirmation: 2019/07/18
Last earnings filing: 2019/04/26
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.